- Jul 17
- 1 min read
Eirgen Programme Receives Regulatory Approval in Vietnam
We are pleased to share the recent regulatory approval of one of our key programmes in Vietnam, marking an important milestone in expanding access to medicines in a new market. This achievement reflects the strength of collaboration across Eirgen, with teams working together to support the submission process, share knowledge, and deliver a successful outcome.
The approval is a testament to the dedication and expertise of colleagues across the business, particularly our Regulatory Affairs team, who led the submission process from start to finish and played a critical role in bringing this programme to approval.
Commenting on the milestone, James Murphy, COO, said:
"Regulatory approvals such as this are the result of strong teamwork, technical expertise, and a shared commitment to excellence. This achievement demonstrates the value of collaboration across our organisation and our ability to support patients by bringing important medicines to new markets. I would like to thank everyone involved, particularly our Regulatory Affairs team, for their dedication and hard work throughout the process."
As Eirgen continues to support pharmaceutical partners around the world, milestones like this reinforce our commitment to quality, regulatory excellence, and improving access to medicines for patients globally.
Comments